Composition for preventing or treating liver diseases
A composition and group technology, applied in the direction of drug combination, boron compound active ingredients, hydroxyl compound active ingredients, etc., can solve problems such as the lack of joint use of liver disease treatment technology, imperfect effect of liver fibrosis, etc., to achieve good liver disease prevention or Therapeutic effect, prevention or treatment of liver disease, effect of reduction of liver damage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
experiment example 1
[0078]
[0079] 1. Experimental materials
[0080] AML12 cells (CRL-2254) were purchased from the American Type Culture Collection (ATCC). Colchicine (C9754), sodium palmitate (Sodium palmitate; P9767), superoxide anion fluorescent probe (dihydroethidium, DHE; D7008) were purchased from Sigma-Aldrich Company. Alogliptin (brand name: Nesina) was purchased from Takeda Pharmaceutical, South Korea, igagliptin (brand name: Suganon) was purchased from East Asia ST Company, gemagliptin (brand name: Zemiglo) was purchased from LG Life Sciences, and Gliptin (brand name: Onglyza) was purchased from Bristol-Myers Squibb, sitagliptin (brand name: Januvia) was purchased from Merck, and treglitin (brand name: Ziten) was purchased from Glenmark Pharmaceuticals. Vildagliptin (brand name: Galvus) was purchased from Novartis Pharmaceuticals.
[0081] 2. Cell Culture and Drug Treatment
[0082] Mouse hepatocyte-AML12 cells were treated at 37°C under 95% air and 5% CO2 environment, containin...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


